Home / Articles / NMR screening and studies of target--ligand interactions

NMR screening and studies of target--ligand interactions

Vladimir Ivanovich Polshakov 1
Vladimir Ivanovich Polshakov
, 
Evgeniy Andreevich Batuev 1
Evgeniy Andreevich Batuev
, 
Alexey Borisovich Mantsyzov 1
Alexey Borisovich Mantsyzov
1 Department of Fundamental Medicine, M.V.Lomonosov Moscow State University
10.1070/RCR4836
Published 30 November 2018
Review , RCR4836, Volume 88, Issue 1, 59-98
9
Share
Cite this
GOST
 | 
Cite this
GOST
Copy cite
Polshakov V. I., Batuev E. A., Mantsyzov A. B. NMR screening and studies of target--ligand interactions // Russian Chemical Reviews. 2018. Vol. 88. No. 1. pp. 59-98.
GOST all authors (up to 50)
Copy cite
Polshakov V. I., Batuev E. A., Mantsyzov A. B. NMR screening and studies of target--ligand interactions // Russian Chemical Reviews. 2018. Vol. 88. No. 1. pp. 59-98.
RIS
 | 
Cite this
RIS
Copy cite
TY - JOUR
DO - 10.1070/RCR4836
UR - https://rcr.colab.ws/publications/10.1070/RCR4836
TI - NMR screening and studies of target--ligand interactions
T2 - Russian Chemical Reviews
AU - Polshakov, Vladimir Ivanovich
AU - Batuev, Evgeniy Andreevich
AU - Mantsyzov, Alexey Borisovich
PY - 2018
DA - 2018/11/30
PB - ANO Editorial Board of the journal Uspekhi Khimii
SP - 59-98
IS - 1
VL - 88
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors)
Copy cite
@article{2018_Polshakov,
author = {Vladimir Ivanovich Polshakov and Evgeniy Andreevich Batuev and Alexey Borisovich Mantsyzov},
title = {NMR screening and studies of target--ligand interactions},
journal = {Russian Chemical Reviews},
year = {2018},
volume = {88},
publisher = {ANO Editorial Board of the journal Uspekhi Khimii},
month = {Nov},
url = {https://rcr.colab.ws/publications/10.1070/RCR4836},
number = {1},
pages = {59--98},
doi = {10.1070/RCR4836}
}
MLA
Cite this
MLA
Copy cite
Polshakov, Vladimir Ivanovich, et al. “NMR screening and studies of target--ligand interactions.” Russian Chemical Reviews, vol. 88, no. 1, Nov. 2018, pp. 59-98. https://rcr.colab.ws/publications/10.1070/RCR4836.
Views / Visits / Downloads
41 / 40 / 10

Abstract

Nuclear magnetic resonance (NMR) spectroscopy is one of the leading biophysical methods used in the search for and design of physiologically active compounds considered as potential drugs. The review concerns modern NMR techniques used to study the binding of low-molecular-mass compounds to biomacromolecular targets. The most promising methods of NMR screening and strategies for rational lead design are discussed. They were used to design drugs that have been approved for the use in medical practice or are in the final stages of clinical trials. Examples are given of the application of the fragment-based drug design and NMR screening techniques to the design of novel drugs.

The bibliography includes 252 references.

Funders

Russian Science Foundation
14-14-00598

References

2.
Twenty years on: the impact of fragments on drug discovery
Erlanson D.A., Fesik S.W., Hubbard R.E., Jahnke W., Jhoti H.
Nature Reviews Drug Discovery , 2016
3.
Lessons from 60 years of pharmaceutical innovation
Munos B.
Nature Reviews Drug Discovery , 2009
4.
rcr_88_1_59_bib4
Giersiefen
2003
5.
rcr_88_1_59_bib5
Friedman
2010
6.
Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery
Blundell T.L., Sibanda B.L., Montalvão R.W., Brewerton S., Chelliah V., Worth C.L., Harmer N.J., Davies O., Burke D.
Philosophical Transactions of the Royal Society B: Biological Sciences , 2006
7.
Genome-wide association studies: progress and potential for drug discovery and development
Kingsmore S.F., Lindquist I.E., Mudge J., Gessler D.D., Beavis W.D.
Nature Reviews Drug Discovery , 2008
8.
Chemical proteomics and its application to drug discovery.
Jeffery D.A., Bogyo M.
Current Opinion in Biotechnology , 2003
9.
Phenotypic screens as a renewed approach for drug discovery.
Zheng W., Thorne N., McKew J.C.
Drug Discovery Today , 2013
10.
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat J.G., Vincent F., Lee J.A., Eder J., Prunotto M.
Nature Reviews Drug Discovery , 2017
11.
Drugs, their targets and the nature and number of drug targets
Imming P., Sinning C., Meyer A.
Nature Reviews Drug Discovery , 2006
12.
A comprehensive map of molecular drug targets
Santos R., Ursu O., Gaulton A., Bento A.P., Donadi R.S., Bologa C.G., Karlsson A., Al-Lazikani B., Hersey A., Oprea T.I., Overington J.P.
Nature Reviews Drug Discovery , 2016
13.
How were new medicines discovered?
Swinney D.C., Anthony J.
Nature Reviews Drug Discovery , 2011
14.
How many drug targets are there?
Overington J.P., Al-Lazikani B., Hopkins A.L.
Nature Reviews Drug Discovery , 2006
16.
Molecular Properties That Influence the Oral Bioavailability of Drug Candidates
Veber D.F., Johnson S.R., Cheng H., Smith B.R., Ward K.W., Kopple K.D.
Journal of Medicinal Chemistry , 2002
17.
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd H., Gifford E.
Nature Reviews Drug Discovery , 2003
18.
NMR-based screening in drug discovery.
Hajduk P.J., Meadows R.P., Fesik S.W.
Quarterly Reviews of Biophysics , 1999
19.
Applications of NMR in drug discovery.
Roberts G.C.
Drug Discovery Today , 2000
20.
Nuclear magnetic resonance as a tool in drug discovery, metabolism and disposition.
Susan Sondej Pochapsky, Thomas C. Pochapsky
Current Topics in Medicinal Chemistry , 2001
21.
Nmr in drug discovery
Pellecchia M., Sem D.S., Wüthrich K.
Nature Reviews Drug Discovery , 2002
22.
NMR screening techniques in drug discovery and drug design
Stockman B.J., Dalvit C.
Progress in Nuclear Magnetic Resonance Spectroscopy , 2002
24.
Theory and applications of NMR-based screening in pharmaceutical research.
Lepre C.A., Moore J.M., Peng J.W.
Chemical Reviews , 2004
25.
NMR experiments for lead generation in drug discovery
Peng J.W., Moore J., Abdul-Manan N.
Progress in Nuclear Magnetic Resonance Spectroscopy , 2004
26.
Application of NMR screening in drug discovery.
Fejzo J., Lepre C., Xie X.
Current Topics in Medicinal Chemistry , 2003
27.
NMR methods for the determination of protein–ligand dissociation constants
FIELDING L.
Progress in Nuclear Magnetic Resonance Spectroscopy , 2007
28.
Quantitative analysis of protein-ligand interactions by NMR.
Furukawa A., Konuma T., Yanaka S., Sugase K.
Progress in Nuclear Magnetic Resonance Spectroscopy , 2016
30.
rcr_88_1_59_bib30
Bentley
2017
33.
rcr_88_1_59_bib33
Jhoti
2008
34.
Fragment‐based drug discovery as alternative strategy to the drug development for neglected diseases
Mello J.D., Gomes R.A., Vital-Fujii D.G., Ferreira G.M., Trossini G.H.
Chemical Biology and Drug Design , 2017
35.
NMR in structure-based drug design.
Carneiro M., AB E., Theisgen S., Siegal G.
Essays in Biochemistry , 2017
36.
“Rules of Engagement” of Protein–Glycoconjugate Interactions: A Molecular View Achievable by using NMR Spectroscopy and Molecular Modeling
Marchetti R., Perez S., Arda A., Imberty A., Jimenez-Barbero J., Silipo A., Molinaro A.
ChemistryOpen , 2016
38.
Biophysics in drug discovery: impact, challenges and opportunities
Renaud J., Chung C., Danielson U.H., Egner U., Hennig M., Hubbard R.E., Nar H.
Nature Reviews Drug Discovery , 2016
39.
rcr_88_1_59_bib39
Miller
J. Biol. Chem. , 1983
41.
rcr_88_1_59_bib41
Fersht
1999
42.
Potential energy curves for cation-pi interactions: off-axis configurations are also attractive.
Marshall M.S., Steele R.P., Thanthiriwatte K.S., Sherrill C.D.
Journal of Physical Chemistry A , 2009
43.
Enthalpy of hydrogen bond formation in a protein-ligand binding reaction.
Connelly P.R., Aldape R.A., Bruzzese F.J., Chambers S.P., Fitzgibbon M.J., Fleming M.A., Itoh S., Livingston D.J., Navia M.A., Thomson J.A.
Proceedings of the National Academy of Sciences of the United States of America , 1994
44.
π-Stacking Interactions
McGaughey G.B., Gagné M., Rappé A.K.
Journal of Biological Chemistry , 1998
47.
Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect.
Page M.I., Jencks W.P.
Proceedings of the National Academy of Sciences of the United States of America , 1971
48.
Ligand efficiency: a useful metric for lead selection.
Hopkins A.L., Groom C.R., Alex A.
Drug Discovery Today , 2004
50.
rcr_88_1_59_bib50
Rarey
2001
51.
Impact of high-throughput screening in biomedical research
Macarron R., Banks M.N., Bojanic D., Burns D.J., Cirovic D.A., Garyantes T., Green D.V., Hertzberg R.P., Janzen W.P., Paslay J.W., Schopfer U., Sittampalam G.S.
Nature Reviews Drug Discovery , 2011
52.
Fragment-based lead discovery
Rees D.C., Congreve, M., Murray C.W., Carr R.
Nature Reviews Drug Discovery , 2004
53.
rcr_88_1_59_bib53
Davis
2017
54.
Fragment-based lead design
Filz O.A., Poroikov V.V.
Russian Chemical Reviews , 2012
55.
Efficiency of hit generation and structural characterization in fragment-based ligand discovery
Larsson A., Jansson A., Åberg A., Nordlund P.
Current Opinion in Chemical Biology , 2011
56.
Fragment library design: efficiently hunting drugs in chemical space.
Boyd S.M., de Kloe G.E.
Drug Discovery Today: Technologies , 2010
57.
A 'rule of three' for fragment-based lead discovery?
Congreve M., Carr R., Murray C., Jhoti H.
Drug Discovery Today , 2003
58.
The 'rule of three' for fragment-based drug discovery: where are we now?
Jhoti H., Williams G., Rees D.C., Murray C.W.
Nature Reviews Drug Discovery , 2013
59.
On the attribution and additivity of binding energies.
Jencks W.P.
Proceedings of the National Academy of Sciences of the United States of America , 1981
60.
Ligand efficiency and fragment-based drug discovery
Bembenek S.D., Tounge B.A., Reynolds C.H.
Drug Discovery Today , 2009
61.
Ligand efficiency as a guide in fragment hit selection and optimization.
Schultes S., de Graaf C., Haaksma E.E., de Esch I.J., Leurs R., Krämer O.
Drug Discovery Today: Technologies , 2010
62.
Fragment-based lead discovery using X-ray crystallography.
Hartshorn M.J., Murray C.W., Cleasby A., Frederickson M., Tickle I.J., Jhoti H.
Journal of Medicinal Chemistry , 2004
63.
High-throughput crystallography for lead discovery in drug design
Blundell T.L., Jhoti H., Abell C.
Nature Reviews Drug Discovery , 2002
64.
Fragment-based screening using X-ray crystallography and NMR spectroscopy.
Jhoti H., Cleasby A., Verdonk M., Williams G.
Current Opinion in Chemical Biology , 2007
65.
Optical biosensors in drug discovery
Cooper M.A.
Nature Reviews Drug Discovery , 2002
66.
Biosensor-based small molecule fragment screening with biolayer interferometry
Wartchow C.A., Podlaski F., Li S., Rowan K., Zhang X., Mark D., Huang K.
Journal of Computer-Aided Molecular Design , 2011
67.
Adding calorimetric data to decision making in lead discovery: a hot tip
Ladbury J.E., Klebe G., Freire E.
Nature Reviews Drug Discovery , 2009
69.
Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes
Hofstadler S.A., Sannes-Lowery K.A.
Nature Reviews Drug Discovery , 2006
70.
rcr_88_1_59_bib70
Ohlson
2016
71.
Protein-binding assays in biological liquids using microscale thermophoresis
Wienken C.J., Baaske P., Rothbauer U., Braun D., Duhr S.
Nature Communications , 2010
72.
Optical thermophoresis for quantifying the buffer dependence of aptamer binding.
Baaske P., Wienken C., Reineck P., Duhr S., Braun D.
Angewandte Chemie - International Edition , 2010
73.
Using chemical shift perturbation to characterise ligand binding.
Williamson M.P.
Progress in Nuclear Magnetic Resonance Spectroscopy , 2013
74.
Biomolecular NMR: a chaperone to drug discovery
BETZ M., SAXENA K., SCHWALBE H.
Current Opinion in Chemical Biology , 2006
75.
NMR-based analysis of protein–ligand interactions
Cala O., Guillière F., Krimm I.
Analytical and Bioanalytical Chemistry , 2013
76.
Perspectives on NMR in drug discovery: a technique comes of age
Pellecchia M., Bertini I., Cowburn D., Dalvit C., Giralt E., Jahnke W., James T.L., Homans S.W., Kessler H., Luchinat C., Meyer B., Oschkinat H., Peng J., Schwalbe H., Siegal G., et. al.
Nature Reviews Drug Discovery , 2008
77.
Fragment-based drug discovery using NMR spectroscopy
Harner M.J., Frank A.O., Fesik S.W.
Journal of Biomolecular NMR , 2013
78.
NMR spectroscopy tools for structure-aided drug design.
Homans S.W.
Angewandte Chemie - International Edition , 2004
79.
NMR in structural proteomics and beyond.
Banci L., Bertini I., Luchinat C., Mori M.
Progress in Nuclear Magnetic Resonance Spectroscopy , 2010
80.
rcr_88_1_59_bib80
Rule
2006
81.
Stable isotope labeling methods for protein NMR spectroscopy
Ohki S., Kainosho M.
Progress in Nuclear Magnetic Resonance Spectroscopy , 2008
83.
NMR-based solution structure of the complex of Lactobacillus casei dihydrofolate reductase with trimethoprim and NADPH [1]
Polshakov V.I., Smirnov E.G., Birdsall B., Kelly G., Feeney J.
Journal of Biomolecular NMR , 2002
84.
Labelling approaches for protein structural studies by solution-state and solid-state NMR
Lian L., Middleton D.A.
Progress in Nuclear Magnetic Resonance Spectroscopy , 2001
86.
rcr_88_1_59_bib86
Gemmecker
J. Magn. Reson. , 1992
87.
Solution structure of human dihydrofolate reductase in its complex with trimethoprim and NADPH
Kovalevskaya N.V., Smurnyy Y.D., Polshakov V.I., Birdsall B., Bradbury A.F., Frenkiel T., Feeney J.
Journal of Biomolecular NMR , 2005
88.
Ordering of the N-terminus of human MDM2 by small molecule inhibitors.
Michelsen K., Jordan J.B., Lewis J., Long A.M., Yang E., Rew Y., Zhou J., Yakowec P., Schnier P.D., Huang X., Poppe L.
Journal of the American Chemical Society , 2012
89.
Solution structure of wild-type human matrix metalloproteinase 12 (MMP-12) in complex with a tight-binding inhibitor
Markus M.A., Dwyer B., Wolfrom S., Li J., Li W., Malakian K., Wilhelm J., Tsao D.H.
Journal of Biomolecular NMR , 2008
90.
Validation of a new restraint docking method for solution structure determinations of protein-ligand complexes
Polshakov V.I., Morgan W.D., Birdsall B., Feeney J.
Journal of Biomolecular NMR , 1999
91.
NMR-Based Determination of the 3D Structure of the Ligand-Protein Interaction Site without Protein Resonance Assignment.
Orts J., Wälti M.A., Marsh M., Vera L., Gossert A.D., Güntert P., Riek R.
Journal of the American Chemical Society , 2016
95.
Chapter 1 Nuclear magnetic resonance of organic charge-transfer complexes
Foster R., Fyfe C.A.
Progress in Nuclear Magnetic Resonance Spectroscopy , 1969
96.
Interplay of histidine residues of the Alzheimer's disease Aβ peptide governs its Zn-induced oligomerization
Istrate A.N., Kozin S.A., Zhokhov S.S., Mantsyzov A.B., Kechko O.I., Pastore A., Makarov A.A., Polshakov V.I.
Scientific Reports , 2016
98.
NMR line shapes and multi-state binding equilibria
Kovrigin E.L.
Journal of Biomolecular NMR , 2012
99.
Two-Dimensional NMR Lineshape Analysis
Waudby C.A., Ramos A., Cabrita L.D., Christodoulou J.
Scientific Reports , 2016
102.
Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics
Hothersall J.D., Guo D., Sarda S., Sheppard R.J., Chen H., Keur W., Waring M.J., IJzerman A.P., Hill S.J., Dale I.L., Rawlins P.B.
Molecular Pharmacology , 2016
103.
Complexes formed between calmodulin and the antagonists J-8 and TFP in solution.
Craven C.J., Whitehead B., Jones S.K., Thulin E., Blackburn G.M., Waltho J.P.
Biochemistry , 1996
104.
rcr_88_1_59_bib104
Johnson
Biochemistry , 1998
106.
Slow dynamics in folded and unfolded states of an SH3 domain.
Tollinger M., Skrynnikov N.R., Mulder F.A., Forman-Kay J.D., Kay L.E.
Journal of the American Chemical Society , 2001
107.
Overview of Relaxation Dispersion NMR Spectroscopy to Study Protein Dynamics and Protein‐Ligand Interactions
Walinda E., Morimoto D., Sugase K.
Current Protocols in Protein Science , 2018
109.
Measurement of Ligand–Target Residence Times by 1H Relaxation Dispersion NMR Spectroscopy
Moschen T., Grutsch S., Juen M.A., Wunderlich C.H., Kreutz C., Tollinger M.
Journal of Medicinal Chemistry , 2016
110.
Ligand-Detected Relaxation Dispersion NMR Spectroscopy: Dynamics of preQ1-RNA Binding
Moschen T., Wunderlich C.H., Spitzer R., Levic J., Micura R., Tollinger M., Kreutz C.
Angewandte Chemie , 2014
111.
Dynamics of ligand binding from 13C NMR relaxation dispersion at natural abundance.
Zintsmaster J.S., Wilson B.D., Peng J.W.
Journal of the American Chemical Society , 2008
113.
Label-free NMR-based dissociation kinetics determination
Trigo-Mouriño P., Griesinger C., Lee D.
Journal of Biomolecular NMR , 2017
114.
rcr_88_1_59_bib114
Job
Ann. Chim. Fr. , 1928
115.
Method of Continuous Variations: Applications of Job Plots to the Study of Molecular Associations in Organometallic Chemistry
Renny J.S., Tomasevich L.L., Tallmadge E.H., Collum D.B.
Angewandte Chemie - International Edition , 2013
117.
On the use of the method of continuous variations
Gil V.M., Oliveira N.C.
Journal of Chemical Education , 1990
118.
The English (H6R) familial Alzheimer's disease mutation facilitates zinc-induced dimerization of the amyloid-β metal-binding domain
Kozin S.A., Kulikova A.A., Istrate A.N., Tsvetkov P.O., Zhokhov S.S., Mezentsev Y.V., Kechko O.I., Ivanov A.S., Polshakov V.I., Makarov A.A.
Metallomics , 2015
120.
rcr_88_1_59_bib120
Hajdük
J. Am. Chem. Soc. , 1997
122.
10.1021/ja963654+
123.
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W.
Science , 1996
124.
Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR
Hajduk P.J., Sheppard G., Nettesheim D.G., Olejniczak E.T., Shuker S.B., Meadows R.P., Steinman D.H., Carrera G.M., Marcotte P.A., Severin J., Walter K., Smith H., Gubbins E., Simmer R., Holzman T.F., et. al.
Journal of the American Chemical Society , 1997
127.
TROSY and CRINEPT: NMR with large molecular and supramolecular structures in solution.
Riek R., Pervushin K., Wüthrich K.
Trends in Biochemical Sciences , 2000
128.
NMR-Based Screening of Proteins Containing 13C-Labeled Methyl Groups
Hajduk P.J., Augeri D.J., Mack J., Mendoza R., Yang J., Betz S.F., Fesik S.W.
Journal of the American Chemical Society , 2000
130.
Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak A.M., Slassi M., Kay L.E., Schimmer A.D.
Journal of the National Cancer Institute , 2011
131.
Hajduk P.J.
Molecular Interventions , 2006
132.
RAMPED-UP NMR: multiplexed NMR-based screening for drug discovery.
Zartler E.R., Hanson J., Jones B.E., Kline A.D., Martin G., Mo H., Shapiro M.J., Wang R., Wu H., Yan J.
Journal of the American Chemical Society , 2003
133.
Cell-free protein production and labeling protocol for NMR-based structural proteomics
Vinarov D.A., Lytle B.L., Peterson F.C., Tyler E.M., Volkman B.F., Markley J.L.
Nature Methods , 2004
134.
A combinatorial selective labeling method for the assignment of backbone amide NMR resonances.
Parker M.J., Aulton-Jones M., Hounslow A.M., Craven C.J.
Journal of the American Chemical Society , 2004
135.
Fluorinated Aromatic Amino Acids Are Sensitive 19F NMR Probes for Bromodomain-Ligand Interactions
Mishra N.K., Urick A.K., Ember S.W., Schönbrunn E., Pomerantz W.C.
ACS Chemical Biology , 2014
136.
Protein-observed 19F-NMR for fragment screening, affinity quantification and druggability assessment
Gee C.T., Arntson K.E., Urick A.K., Mishra N.K., Hawk L.M., Wisniewski A.J., Pomerantz W.C.
Nature Protocols , 2016
137.
Protein-Observed Fluorine NMR Is a Complementary Ligand Discovery Method to 1H CPMG Ligand-Observed NMR.
Urick A.K., Calle L.P., Espinosa J.F., Hu H., Pomerantz W.C.
ACS Chemical Biology , 2016
139.
19F NMR as a Probe of Ligand Interactions with the iNOS Binding site of SPRY Domain‐Containing SOCS Box Protein 2
Leung E.W., Yagi H., Harjani J.R., Mulcair M.D., Scanlon M.J., Baell J.B., Norton R.S.
Chemical Biology and Drug Design , 2014
140.
Ligand-induced conformational change of Plasmodium falciparum AMA1 detected using 19F NMR.
Ge X., MacRaild C.A., Devine S.M., Debono C.O., Wang G., Scammells P.J., Scanlon M.J., Anders R.F., Foley M., Norton R.S.
Journal of Medicinal Chemistry , 2014
141.
10.1021/ja001241+
142.
Protein NMR Using Paramagnetic Ions
Otting G.
Annual Review of Biophysics , 2010
143.
Paramagnetic Ligand Tagging To Identify Protein Binding Sites
Brath U., Swamy S.I., Veiga A.X., Tung C., Van Petegem F., Erdélyi M.
Journal of the American Chemical Society , 2015
144.
TROSY-based NMR experiments for NMR studies of large biomolecules
Zhu G., Yao X.
Progress in Nuclear Magnetic Resonance Spectroscopy , 2008
145.
Mapping the interaction between the hemophore HasA and its outer membrane receptor HasR using CRINEPT-TROSY NMR spectroscopy.
Caillet-Saguy C., Piccioli M., Turano P., Izadi-Pruneyre N., Delepierre M., Bertini I., Lecroisey A.
Journal of the American Chemical Society , 2009
147.
rcr_88_1_59_bib147
Davis
2016
148.
rcr_88_1_59_bib148
Kim
2015
150.
Sensitivity enhancement in saturation transfer difference (STD) experiments through optimized excitation schemes
Cutting B., Shelke S.V., Dragic Z., Wagner B., Gathje H., Kelm S., Ernst B.
Magnetic Resonance in Chemistry , 2007
151.
Two-dimensional heteronuclear saturation transfer difference NMR reveals detailed integrin αvβ6 protein-peptide interactions.
Wagstaff J.L., Vallath S., Marshall J.F., Williamson R.A., Howard M.J.
Chemical Communications , 2010
156.
Fluorinated carbohydrates as lectin ligands: versatile sensors in 19F-detected saturation transfer difference NMR spectroscopy.
Diercks T., Ribeiro J., Cañada F.J., André S., Jiménez-Barbero J., Gabius H.
Chemistry - A European Journal , 2009
158.
Direct detection of ligand binding to Sepharose-immobilised protein using saturation transfer double difference (STDD) NMR spectroscopy.
Haselhorst T., Münster-Kühnel A.K., Oschlies M., Tiralongo J., Gerardy-Schahn R., Itzstein M.V.
Biochemical and Biophysical Research Communications , 2007
159.
WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability
Dalvit C., Fogliatto G., Stewart A., Veronesi M., Stockman B.
Journal of Biomolecular NMR , 2001
160.
Time efficient detection of protein–ligand interactions with the polarization optimized PO-WaterLOGSY NMR experiment
Gossert A.D., Henry C., Blommers M.J., Jahnke W., Fernández C.
Journal of Biomolecular NMR , 2009
161.
Aroma WaterLOGSY: a fast and sensitive screening tool for drug discovery
Hu J., Eriksson P., Kern G.
Magnetic Resonance in Chemistry , 2010
162.
Comparison of the sensitivities of WaterLOGSY and saturation transfer difference NMR experiments
Antanasijevic A., Ramirez B., Caffrey M.
Journal of Biomolecular NMR , 2014
163.
rcr_88_1_59_bib163
Fürihata
Pharm. Anal. Chem. (Open Access) , 2016
164.
NMR screening of potential inhibitors of methionine γ-lyase from Citrobacter freundii
Batuev E.A., Lisunov A.Y., Morozova E.A., Klochkov V.V., Anufrieva N.V., Demidkina T.V., Polshakov V.I.
Molecular Biology , 2014
165.
Determination of protein–ligand binding affinity by NMR: observations from serum albumin model systems
Fielding L., Rutherford S., Fletcher D.
Magnetic Resonance in Chemistry , 2005
166.
rcr_88_1_59_bib166
Hüang
Sci. Rep. , 2017
167.
Fluorine-NMR experiments for high-throughput screening: theoretical aspects, practical considerations, and range of applicability.
Dalvit C., Fagerness P.E., Hadden D.T., Sarver R.W., Stockman B.J.
Journal of the American Chemical Society , 2003
168.
Sensitivity improvement in 19F NMR-based screening experiments: theoretical considerations and experimental applications.
Dalvit C., Mongelli N., Papeo G., Giordano P., Veronesi M., Moskau D., Kümmerle R.
Journal of the American Chemical Society , 2005
169.
Reliable high-throughput functional screening with 3-FABS.
Dalvit C., Ardini E., Fogliatto G.P., Mongelli N., Veronesi M.
Drug Discovery Today , 2004
171.
Development of Fragment‐Based n‐FABS NMR Screening Applied to the Membrane Enzyme FAAH
Lambruschini C., Veronesi M., Romeo E., Garau G., Bandiera T., Piomelli D., Scarpelli R., Dalvit C.
ChemBioChem , 2013
172.
Fluorine nuclear magnetic resonance-based assay in living mammalian cells.
Veronesi M., Giacomina F., Romeo E., Castellani B., Ottonello G., Lambruschini C., Garau G., Scarpelli R., Bandiera T., Piomelli D., Dalvit C.
Analytical Biochemistry , 2016
173.
Spin label enhanced NMR screening.
Jahnke W., Rüdisser S., Zurini M.
Journal of the American Chemical Society , 2001
179.
TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery.
Vanwetswinkel S., Heetebrij R.J., van Duynhoven J., Hollander J.G., Filippov D.V., Hajduk P.J., Siegal G.
Chemistry & Biology , 2005
180.
One-dimensional DOSY.
Loening N.M., Keeler J., Morris G.A.
Journal of Magnetic Resonance , 2001
181.
Pulse sequences for high-resolution diffusion-ordered spectroscopy (HR-DOSY)
Pelta M.D., Barjat H., Morris G.A., Davis A.L., Hammond S.J.
Magnetic Resonance in Chemistry , 1998
183.
The INPHARMA method: protein-mediated interligand NOEs for pharmacophore mapping.
Sánchez-Pedregal V.M., Reese M., Meiler J., Blommers M.J., Griesinger C., Carlomagno T.
Angewandte Chemie - International Edition , 2005
184.
SAR by ILOEs: an NMR-based approach to reverse chemical genetics.
Becattini B., Pellecchia M.
Chemistry - A European Journal , 2006
185.
Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules.
Becattini B., Sareth S., Zhai D., Crowell K.J., Leone M., Reed J.C., Pellecchia M.
Chemistry & Biology , 2004
186.
SALMON: solvent accessibility, ligand binding, and mapping of ligand orientation by NMR spectroscopy.
Ludwig C., Michiels P.J., Wu X., Kavanagh K.L., Pilka E., Jansson A., Oppermann U., Günther U.L.
Journal of Medicinal Chemistry , 2007
188.
The INPHARMA technique for pharmacophore mapping: A theoretical guide to the method.
Orts J., Griesinger C., Carlomagno T.
Journal of Magnetic Resonance , 2009
189.
Discovery of ligands for a novel target, the human telomerase RNA, based on flexible-target virtual screening and NMR.
Gómez Pinto I., Guilbert C., Ulyanov N.B., Stearns J., James T.L.
Journal of Medicinal Chemistry , 2008
190.
Accounting for conformational variability in protein-ligand docking with NMR-guided rescoring.
Skjærven L., Codutti L., Angelini A., Grimaldi M., Latek D., Monecke P., Dreyer M.K., Carlomagno T.
Journal of the American Chemical Society , 2013
191.
Structural basis of the activity of the microtubule-stabilizing agent epothilone a studied by NMR spectroscopy in solution.
Reese M., Sánchez-Pedregal V., Kubicek K., Meiler J., Blommers M. ., Griesinger C., Carlomagno T.
Angewandte Chemie - International Edition , 2007
192.
Structure-based approach to improve a small-molecule inhibitor by the use of a competitive peptide ligand.
Ono K., Takeuchi K., Ueda H., Morita Y., Tanimura R., Shimada I., Takahashi H.
Angewandte Chemie - International Edition , 2014
193.
Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin
Sivertsen A., Isaksson J., Leiros H.S., Svenson J., Svendsen J., Brandsdal B.O.
BMC Structural Biology , 2014
194.
rcr_88_1_59_bib194
Krimm
2012
195.
Binding mode characterization of novel RNA polymerase inhibitors using a combined biochemical and NMR approach.
Fruth M., Plaza A., Hinsberger S., Sahner J.H., Haupenthal J., Bischoff M., Jansen R., Müller R., Hartmann R.W.
ACS Chemical Biology , 2014
196.
NMR-based techniques in the hit identification and optimisation processes
Pellecchia M., Becattini B., Crowell K.J., Fattorusso R., Forino M., Fragai M., Jung D., Mustelin T., Tautz L.
Expert Opinion on Therapeutic Targets , 2004
198.
Overview of Probing Protein‐Ligand Interactions Using NMR
Aguirre C., Cala O., Krimm I.
Current Protocols in Protein Science , 2015
199.
Structure–activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid
Becattini B., Culmsee C., Leone M., Zhai D., Zhang X., Crowell K.J., Rega M.F., Landshamer S., Reed J.C., Plesnila N., Pellecchia M.
Proceedings of the National Academy of Sciences of the United States of America , 2006
200.
The effect of relaxation on the epitope mapping by saturation transfer difference NMR.
Yan J., Kline A.D., Mo H., Shapiro M.J., Zartler E.R.
Journal of Magnetic Resonance , 2003
202.
Identification of the Binding Site of an Allosteric Ligand Using STD-NMR, Docking, and CORCEMA-ST Calculations
Zhang W., Li R., Shin R., Wang Y., Padmalayam I., Zhai L., Krishna N.R.
ChemMedChem , 2013
203.
rcr_88_1_59_bib203
Yuan
Biochemistry , 2005
205.
Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG).
Schultze P., Macaya R.F., Feigon J.
Journal of Molecular Biology , 1994
206.
rcr_88_1_59_bib206
Wang
Biochemistry , 1993
207.
Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution.
Macaya R.F., Schultze P., Smith F.W., Roe J.A., Feigon J.
Proceedings of the National Academy of Sciences of the United States of America , 1993
209.
Determination of the binding specificity of the 12S subunit of the transcarboxylase by saturation transfer difference NMR.
Peikert C., Seeger K., Bhat R.K., Berger S.
Organic and Biomolecular Chemistry , 2004
210.
SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes.
Hajduk P.J., Mack J.C., Olejniczak E.T., Park C., Dandliker P.J., Beutel B.A.
Journal of the American Chemical Society , 2004
212.
rcr_88_1_59_bib212
Siebert
2003
213.
rcr_88_1_59_bib213
Clore
J. Magn. Reson. , 1983
214.
Conformation of ligands bound to the muscarinic acetylcholine receptor.
Furukawa H., Hamada T., Hayashi M.K., Haga T., Muto Y., Hirota H., Yokoyama S., Nagasawa K., Ishiguro M.
Molecular Pharmacology , 2002
216.
Screening mixtures for biological activity by NMR.
Meyer B., Weimar T., Peters T.
FEBS Journal , 1997
217.
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.
Fejzo J., Lepre C.A., Peng J.W., Bemis G.W., Ajay, Murcko M.A., Moore J.M.
Chemistry & Biology , 1999
218.
rcr_88_1_59_bib218
Peng
2001
219.
rcr_88_1_59_bib219
Johnson
J. Am. Chem. Soc , 2003
220.
Computer-Aided Design of Fragment Mixtures for NMR-Based Screening
Arroyo X., Goldflam M., Feliz M., Belda I., Giralt E.
PLoS ONE , 2013
221.
NMRmix: A Tool for the Optimization of Compound Mixtures in 1D 1H NMR Ligand Affinity Screens
Stark J.L., Eghbalnia H.R., Lee W., Westler W.M., Markley J.L.
Journal of Proteome Research , 2016
222.
Privileged molecules for protein binding identified from NMR-based screening.
Hajduk P.J., Bures M., Praestgaard J., Fesik S.W.
Journal of Medicinal Chemistry , 2000
223.
NMR-based structural characterization of large protein-ligand interactions
Pellecchia M., Meininger D., Dong Q., Chang E., Jack R., Sem D.S.
Journal of Biomolecular NMR , 2002
225.
ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens.
Huth J.R., Mendoza R., Olejniczak E.T., Johnson R.W., Cothron D.A., Liu Y., Lerner C.G., Chen J., Hajduk P.J.
Journal of the American Chemical Society , 2004
226.
Fragonomics: fragment-based drug discovery.
Zartler E.R., Shapiro M.J.
Current Opinion in Chemical Biology , 2005
227.
Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors
Dahlin J.L., Nelson K.M., Strasser J.M., Barsyte-Lovejoy D., Szewczyk M.M., Organ S., Cuellar M., Singh G., Shrimp J.H., Nguyen N., Meier J.L., Arrowsmith C.H., Brown P.J., Baell J.B., Walters M.A., et. al.
Nature Communications , 2017
228.
ALARM NMR for HTS Triage and Chemical Probe Validation
Dahlin J.L., Cuellar M., Singh G., Nelson K.M., Strasser J.M., Rappe T., Xia Y., Veglia G., Walters M.A.
Current protocols in chemical biology , 2018
229.
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., Fong D., Zhu Y., et. al.
Proceedings of the National Academy of Sciences of the United States of America , 2008
230.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., Burton E.A., Wong B., Tsang G., West B.L., Powell B., et. al.
Nature , 2010
231.
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death
Muchmore S.W., Sattler M., Liang H., Meadows R.P., Harlan J.E., Yoon H.S., Nettesheim D., Chang B.S., Thompson C.B., Wong S., Ng S., Fesik S.W.
Nature , 1996
232.
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., et. al.
Nature , 2005
233.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., Dayton B.D., Ding H., Enschede S.H., Fairbrother W.J., Huang D.C., Hymowitz S.G., Jin S., Khaw S.L., Kovar P.J., et. al.
Nature Medicine , 2013
234.
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
Tap W.D., Wainberg Z.A., Anthony S.P., Ibrahim P.N., Zhang C., Healey J.H., Chmielowski B., Staddon A.P., Cohn A.L., Shapiro G.I., Keedy V.L., Singh A.S., Puzanov I., Kwak E.L., Wagner A.J., et. al.
New England Journal of Medicine , 2015
235.
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.
Scott J.D., Li S.W., Brunskill A.P., Chen X., Cox K., Cumming J.N., Forman M., Gilbert E.J., Hodgson R.A., Hyde L.A., Jiang Q., Iserloh U., Kazakevich I., Kuvelkar R., Mei H., et. al.
Journal of Medicinal Chemistry , 2016
236.
The evolution of amidine-based brain penetrant BACE1 inhibitors.
Oehlrich D., Prokopcova H., Gijsen H.J.
Bioorganic and Medicinal Chemistry Letters , 2014
237.
AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
Eketjäll S., Janson J., Kaspersson K., Bogstedt A., Jeppsson F., Fälting J., Haeberlein S.B., Kugler A.R., Alexander R.C., Cebers G.
Journal of Alzheimer's Disease , 2016
238.
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
Zhang C., Ibrahim P.N., Zhang J., Burton E.A., Habets G., Zhang Y., Powell B., West B.L., Matusow B., Tsang G., Shellooe R., Carias H., Nguyen H., Marimuthu A., Zhang K.Y., et. al.
Proceedings of the National Academy of Sciences of the United States of America , 2013
239.
Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design
Wyatt P.G., Woodhead A.J., Berdini V., Boulstridge J.A., Carr M.G., Cross D.M., Davis D.J., Devine L.A., Early T.R., Feltell R.E., Lewis E.J., McMenamin R.L., Navarro E.F., O’Brien M.A., O’Reilly M., et. al.
Journal of Medicinal Chemistry , 2008
240.
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Howard S., Berdini V., Boulstridge J.A., Carr M.G., Cross D.M., Curry J., Devine L.A., Early T.R., Fazal L., Gill A.L., Heathcote M., Maman S., Matthews J.E., McMenamin R.L., Navarro E.F., et. al.
Journal of Medicinal Chemistry , 2008
241.
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent
Artis D.R., Lin J.J., Zhang C., Wang W., Mehra U., Perreault M., Erbe D., Krupka H.I., England B.P., Arnold J., Plotnikov A.N., Marimuthu A., Nguyen H., Will S., Signaevsky M., et. al.
Proceedings of the National Academy of Sciences of the United States of America , 2009
242.
PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors.
Liebeschuetz J.W., Jones S.D., Morgan P.J., Murray C.W., Rimmer A.D., Roscoe J.M., Waszkowycz B., Welsh P.M., Wylie W.A., Young S.C., Martin H., Mahler J., Brady L., Wilkinson K.
Journal of Medicinal Chemistry , 2002
243.
Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.
Woodhead A.J., Angove H., Carr M.G., Chessari G., Congreve M., Coyle J.E., Cosme J., Graham B., Day P.J., Downham R., Fazal L., Feltell R., Figueroa E., Frederickson M., Lewis J., et. al.
Journal of Medicinal Chemistry , 2010
244.
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Murray C.W., Carr M.G., Callaghan O., Chessari G., Congreve M., Cowan S., Coyle J.E., Downham R., Figueroa E., Frederickson M., Graham B., McMenamin R., O’Brien M.A., Patel S., Phillips T.R., et. al.
Journal of Medicinal Chemistry , 2010
245.
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
Brough P.A., Aherne W., Barril X., Borgognoni J., Boxall K., Cansfield J.E., Cheung K.J., Collins I., Davies N.G., Drysdale M.J., Dymock B., Eccles S.A., Finch H., Fink A., Hayes A., et. al.
Journal of Medicinal Chemistry , 2007
246.
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
Addie M., Ballard P., Buttar D., Crafter C., Currie G., Davies B.R., Debreczeni J., Dry H., Dudley P., Greenwood R., Johnson P.D., Kettle J.G., Lane C., Lamont G., Leach A., et. al.
Journal of Medicinal Chemistry , 2013
247.
rcr_88_1_59_bib247
Wendt
2012
248.
Fragment-to-Lead Medicinal Chemistry Publications in 2015.
Johnson C.N., Erlanson D.A., Murray C.W., Rees D.C.
Journal of Medicinal Chemistry , 2016
249.
NMR screening and hit validation in fragment based drug discovery.
Campos-Olivas R.
Current Topics in Medicinal Chemistry , 2010
250.
Hit discovery and hit-to-lead approaches.
Keserű G.M., Makara G.M.
Drug Discovery Today , 2006
251.
An improved model for fragment-based lead generation at AstraZeneca.
Fuller N., Spadola L., Cowen S., Patel J., Schönherr H., Cao Q., McKenzie A., Edfeldt F., Rabow A., Goodnow R.
Drug Discovery Today , 2016
252.
Fragment-based lead discovery: leads by design.
Carr R.A., Congreve M., Murray C.W., Rees D.C.
Drug Discovery Today , 2005